Canada markets open in 5 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
26.51-1.61 (-5.73%)
At close: 04:00PM EDT
26.65 +0.14 (+0.53%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close28.12
Open27.88
Bid26.46 x 800
Ask27.35 x 1000
Day's Range25.85 - 28.69
52 Week Range15.72 - 146.16
Volume757,419
Avg. Volume1,656,054
Market Cap1.063B
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target EstN/A
  • GlobeNewswire

    Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

    - $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida

  • GlobeNewswire

    Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

    - Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities’ equity rese

  • GlobeNewswire

    Webcast Details for Cassava Sciences’ Upcoming Fireside Chat

    – All Stakeholder Are Welcome to Listen by Webcast – – Event To Be Held Tuesday, April 5th, 9am ET – AUSTIN, Texas, April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO and Eric Schoen, Chief Financial Officer. This event is scheduled to take place on Tuesday, April 5th a